emjreviews.com
Cure8 news brief
IBD Biomarkers Highlight Faecal Calprotectin Value - EMJ
Tests and monitoring
Biomarkers
Fecal calprotectin
Clinical study
Clinicians
Adult patients
Patients On Biologics
Researchers
Why This Matters
Faecal calprotectin appears to be the best non‑invasive test among those studied for distinguishing UC from Crohn’s disease and for reflecting mucosal inflammation. Simpler blood‑based scores may help gauge systemic inflammation but are less specific.
Using these tests alongside endoscopy could improve personalized assessment without replacing it.
Who Should Pay Attention
Clinicians managing IBD, adult patients with Crohn’s disease or ulcerative colitis (especially those on biologics), and researchers interested in IBD biomarkers.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
This report summarizes a retrospective observational study (36 adults on biologic therapy) that compared non‑invasive measures — notably faecal calprotectin, simple blood inflammatory ratios, albumin‑based nutritional scores, and liver fibrosis indices — against standardized endoscopic findings to differentiate Crohn’s disease from ulcerative colitis.
The study found faecal calprotectin had the strongest diagnostic performance for distinguishing UC from Crohn’s (reported AUC 0.74) and was higher in UC (median ~1000 µg/g) than Crohn’s (~310 µg/g).
Albumin‑integrating scores and simple blood‑derived inflammatory markers (eg, neutrophil:lymphocyte ratio, prognostic nutritional index) reflected systemic inflammation moderately well, while liver fibrosis indices performed less well. The investigators recommend using these biomarkers alongside endoscopic assessment rather than alone.
This article is grounded in the journal abstract/paper cited (Ismaiel A et al., J Gastrointestin Liver Dis. 2026). It reports diagnostic comparisons and does not change clinical recommendations.
Keep In Mind
This was a small, retrospective study of 36 patients on biologic therapy; results are preliminary and report diagnostic performance (AUCs) rather than clinical outcomes. The article summarizes a published paper (J Gastrointestin Liver Dis. 2026); the full paper should be reviewed for methods and limitations.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationemjreviews.com
Authorshelenabradbury
Indexed viaGoogle News
Source typeWeb article
PublishedAug 11, 2026, 11:06 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Crohn᾿s Disease and Ulcerative Colitis: The Role of Endoscopic, Hemogram-derived, Nutritional, and Hepatic Scores
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
Evaluation of serum human galectin 3 as a marker of activity in inflammatory bowel disease in comparison to fecal calprotectin.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Fecal surrogate markers strongly correlate with endoscopic findings in pediatric onset inflammatory bowel disease: a retrospective study in Japan
Noninvasive stool markers that track endoscopic inflammation could reduce the need for frequent pediatric endoscopies, easing burden and risk for children with IBD. Strong correlation with endoscopy suggests these tests...